RhumbLine Advisers
ENTA icon

RhumbLine Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

RhumbLine Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$397K Buy
31,403
+2,554
+9% +$34.2K ﹤0.01% 2749
2025
Q4 		$455K Sell
28,849
-2,060
-7% -$26.2K ﹤0.01% 2724
2025
Q3 		$370K Sell
30,909
-1,399
-4% -$11.2K ﹤0.01% 2878
2025
Q2 		$244K Buy
32,308
+1,168
+4% +$7.03K ﹤0.01% 3116
2025
Q1 		$172K Sell
31,140
-5,951
-16% -$36.8K ﹤0.01% 3182
2024
Q4 		$213K Buy
37,091
+926
+3% +$8.88K ﹤0.01% 3161
2024
Q3 		$375K Buy
36,165
+1,599
+5% +$20.9K ﹤0.01% 2899
2024
Q2 		$448K Buy
34,566
+1,548
+5% +$20.9K ﹤0.01% 2759
2024
Q1 		$576K Buy
33,018
+704
+2% +$9.31K ﹤0.01% 2575
2023
Q4 		$304K Sell
32,314
-166
-0.5% -$1.55K ﹤0.01% 2962
2023
Q3 		$363K Sell
32,480
-32,264
-50% -$520K ﹤0.01% 2820
2023
Q2 		$1.39M Buy
64,744
+882
+1% +$26K ﹤0.01% 2121
2023
Q1 		$2.58M Buy
63,862
+3,799
+6% +$181K ﹤0.01% 1677
2022
Q4 		$2.79M Buy
60,063
+60
+0.1% +$2.73K ﹤0.01% 1615
2022
Q3 		$3.11M Buy
60,003
+4,223
+8% +$247K ﹤0.01% 1516
2022
Q2 		$2.64M Buy
55,780
+2,055
+4% +$112K ﹤0.01% 1621
2022
Q1 		$3.82M Sell
53,725
-411
-0.8% -$26.7K ﹤0.01% 1479
2021
Q4 		$4.05M Sell
54,136
-1,024
-2% -$80.4K 0.01% 1484
2021
Q3 		$3.13M Sell
55,160
-6,796
-11% -$336K ﹤0.01% 1636
2021
Q2 		$2.73M Sell
61,956
-4,063
-6% -$199K ﹤0.01% 1792
2021
Q1 		$3.26M Buy
66,019
+762
+1% +$38K ﹤0.01% 1651
2020
Q4 		$2.75M Buy
65,257
+5,698
+10% +$251K ﹤0.01% 1686
2020
Q3 		$2.73M Sell
59,559
-2,084
-3% -$101K ﹤0.01% 1521
2020
Q2 		$3.1M Buy
61,643
+3,714
+6% +$192K 0.01% 1473
2020
Q1 		$2.98M Buy
57,929
+3,820
+7% +$204K 0.01% 1332
2019
Q4 		$3.34M Buy
54,109
+3,220
+6% +$200K 0.01% 1501
2019
Q3 		$3.06M Buy
50,889
+1,214
+2% +$90.2K 0.01% 1483
2019
Q2 		$4.19M Buy
49,675
+2,777
+6% +$250K 0.01% 1297
2019
Q1 		$4.48M Buy
46,898
+145
+0.3% +$13K 0.01% 1241
2018
Q4 		$3.31M Buy
46,753
+8,722
+23% +$669K 0.01% 1345
2018
Q3 		$3.25M Buy
38,031
+481
+1% +$48.2K 0.01% 1384
2018
Q2 		$4.35M Buy
37,550
+691
+2% +$69K 0.01% 1192
2018
Q1 		$2.98M Buy
36,859
+384
+1% +$29.6K 0.01% 1373
2017
Q4 		$2.14M Buy
36,475
+4,476
+14% +$224K ﹤0.01% 1583
2017
Q3 		$1.5M Buy
31,999
+870
+3% +$35K ﹤0.01% 1772
2017
Q2 		$1.12M Sell
31,129
-176
-0.6% -$5.63K ﹤0.01% 1898
2017
Q1 		$964K Buy
31,305
+7,781
+33% +$242K ﹤0.01% 1939
2016
Q4 		$788K Sell
23,524
-1,781
-7% -$51.1K ﹤0.01% 1982
2016
Q3 		$673K Buy
25,305
+965
+4% +$22.4K ﹤0.01% 2035
2016
Q2 		$537K Buy
24,340
+5,974
+33% +$156K ﹤0.01% 2151
2016
Q1 		$539K Buy
18,366
+110
+0.6% +$3.06K ﹤0.01% 2173
2015
Q4 		$603K Buy
18,256
+1,525
+9% +$49.7K ﹤0.01% 2127
2015
Q3 		$605K Buy
16,731
+2,078
+14% +$89.2K ﹤0.01% 2105
2015
Q2 		$659K Buy
14,653
+4,640
+46% +$180K ﹤0.01% 2145
2015
Q1 		$307K Buy
10,013
+1,800
+22% +$70K ﹤0.01% 2597
2014
Q4 		$418K Sell
8,213
-450
-5% -$20.1K ﹤0.01% 2382
2014
Q3 		$343K Sell
8,663
-540
-6% -$21.5K ﹤0.01% 2450
2014
Q2 		$396K Buy
+9,203
New +$351K ﹤0.01% 2418

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RhumbLine Advisers's ENTA Position: Q1 2026 in Review

RhumbLine Advisers increased its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q1 2026, buying an estimated $34.2K and bringing the position to 31,403 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

RhumbLine Advisers first reported a position in ENTA in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.48M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • RhumbLine Advisers held 31,403 shares of Enanta Pharmaceuticals worth $397K as of Q1 2026.
  • RhumbLine Advisers bought 2,554 Enanta Pharmaceuticals shares in Q1 2026, an estimated $34.2K.
  • Enanta Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2749 holding.
  • RhumbLine Advisers first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
  • RhumbLine Advisers's Enanta Pharmaceuticals position peaked at $4.48M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.